Source: HUTCHMED (China) Limited From: globenewswire.com HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer (“TNBC”) or advanced endometrial cancer (“EC”) in the U.S. The first patient was dosed on August 24, 2021. This trial is to explore the potential for …
Zydus Cadila gets USFDA nod for breast cancer treatment drug
From: moneycontrol.com Fulvestrant injection is used alone or in combination with other drugs to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause. Drug firm Zydus Cadila on Friday …
Study finds breast cancer’s response to tumor stiffness may predict bone metastasis
Source: University of Arizona Health Sciences From: eurekalert.org In cases of breast cancer, bone metastasis – when cancer cells spread to new sites in the bone – causes the most breast cancer-related harm and is often incurable in advanced disease. A new study by University of Arizona Health Sciences researchers found that cancer cells become more aggressive when exposed to …
What Treatment Options Exist for Advanced Breast Cancer?
From: healthline.com Having an advanced form of cancer can feel like you have little or no treatment options. But that’s not the case. Find out what options are available to you and start getting on the right type of treatment. Hormone therapy There are several hormone therapies to treat advanced hormone receptor-positive (estrogen receptor-positive or progesterone receptor-positive) breast cancers: Tamoxifen …
Updated Guidelines Focus on Advanced Prostate Cancer
By: Tony Berberabe From: targetedonc.com “Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options.” New guidelines issued jointly by the American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) focus on men withadvanced stage disease and now include new treatments, including the use of PARP …